secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091766
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q2 net revenue +14% to $50.6M; cuts US workforce 75% after pancreatic trial failures
--------------------------------------------------------------------------------

- Net loss narrowed to $15.5M ($0.16/sh) from $87.7M ($0.90) YoY; revenue $50.6M (+14%).
- Raising 2024 roxadustat net product revenue guidance to $135-150M; China total net sales $92.3M (+21%).
- U.S. workforce cut ~75% after pamrevlumab misses endpoints in pancreatic cancer trials (PanCAN, LAPIS).
- Focusing on FG-3246 ADC for mCRPC; Phase 2 combo topline expected 1H 2025, monotherapy study start 1Q 2025.
- Cash, equivalents and AR $147.1M; runway into 2026; CIA approval in China 2H 2024 could trigger $10M milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017024091766/0000950170-24-091766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017024091766/fgen-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer